96 related articles for article (PubMed ID: 1705165)
21. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
Conley BA; Forrest A; Egorin MJ; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1989 Jun; 49(12):3436-40. PubMed ID: 2720696
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical and pharmacokinetic study of taxol.
Wiernik PH; Schwartz EL; Strauman JJ; Dutcher JP; Lipton RB; Paietta E
Cancer Res; 1987 May; 47(9):2486-93. PubMed ID: 2882837
[TBL] [Abstract][Full Text] [Related]
23. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
24. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
25. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN
Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325
[TBL] [Abstract][Full Text] [Related]
26. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
[TBL] [Abstract][Full Text] [Related]
27. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
[TBL] [Abstract][Full Text] [Related]
28. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
[TBL] [Abstract][Full Text] [Related]
29. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
30. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
31. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
Young CW; Fanucchi MP; Declan Walsh T; Baltzer L; Yaldaei S; Stevens YW; Gordon C; Tong W; Rifkind RA; Marks PA
Cancer Res; 1988 Dec; 48(24 Pt 1):7304-9. PubMed ID: 3191501
[TBL] [Abstract][Full Text] [Related]
33. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
34. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
[TBL] [Abstract][Full Text] [Related]
35. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
[TBL] [Abstract][Full Text] [Related]
38. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
39. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.
van Groeningen CJ; Leyva A; O'Brien AM; Gall HE; Pinedo HM
Cancer Res; 1986 Sep; 46(9):4831-6. PubMed ID: 2425959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]